Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. More Details
No risks detected for CERT from our risk checks.
Adequate balance sheet with reasonable growth potential.
Share Price & News
How has Certara's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CERT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: CERT's weekly volatility (6%) has been stable over the past year.
7 Day Return
US Healthcare Services
1 Year Return
US Healthcare Services
Return vs Industry: Insufficient data to determine how CERT performed against the US Healthcare Services industry.
Return vs Market: Insufficient data to determine how CERT performed against the US Market.
Long-Term Price Volatility Vs. Market
How volatile is Certara's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall StCertara, Inc.'s (NASDAQ:CERT) Shift From Loss To Profit
2 months ago | Simply Wall StHave Insiders Been Buying Certara, Inc. (NASDAQ:CERT) Shares This Year?
4 months ago | Simply Wall StHow Much Of Certara, Inc. (NASDAQ:CERT) Do Insiders Own?
Is Certara undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CERT ($25.71) is trading above our estimate of fair value ($9.38)
Significantly Below Fair Value: CERT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CERT is unprofitable, so we can't compare its PE Ratio to the US Healthcare Services industry average.
PE vs Market: CERT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CERT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CERT is good value based on its PB Ratio (4.8x) compared to the US Healthcare Services industry average (6.5x).
How is Certara forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CERT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: CERT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CERT's is expected to become profitable in the next 3 years.
Revenue vs Market: CERT's revenue (14.2% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: CERT's revenue (14.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CERT's Return on Equity is forecast to be low in 3 years time (2.7%).
How has Certara performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CERT is currently unprofitable.
Growing Profit Margin: CERT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CERT's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CERT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CERT is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (28.5%).
Return on Equity
High ROE: CERT has a negative Return on Equity (-5.97%), as it is currently unprofitable.
How is Certara's financial position?
Financial Position Analysis
Short Term Liabilities: CERT's short term assets ($347.6M) exceed its short term liabilities ($63.4M).
Long Term Liabilities: CERT's short term assets ($347.6M) do not cover its long term liabilities ($372.0M).
Debt to Equity History and Analysis
Debt Level: CERT's debt to equity ratio (36.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CERT's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CERT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CERT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 57.4% per year.
What is Certara current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CERT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CERT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CERT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CERT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CERT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bill Feehery (50 yo)
Dr. William F. Feehery, also known as Bill, Ph.D., has served as Chief Executive Officer of the Certara, Inc. and Certara Holdco since June 03, 2019. He serves as a Director at Certara, Inc. He has been th...
CEO Compensation Analysis
Compensation vs Market: Bill's total compensation ($USD3.63M) is below average for companies of similar size in the US market ($USD5.29M).
Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.
Experienced Management: CERT's management team is considered experienced (2.3 years average tenure).
Experienced Board: CERT's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: CERT only recently listed within the past 12 months.
Certara, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Certara, Inc.
- Ticker: CERT
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: US$3.933b
- Shares outstanding: 152.98m
- Website: https://www.certara.com
Number of Employees
- Certara, Inc.
- 100 Overlook Center
- Suite 101
- New Jersey
- United States
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It o...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/23 01:48|
|End of Day Share Price||2021/07/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.